Adam Lorimer

Adam Lorimer serves as a procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of scientific, diagnostic, and biomedical resources. He manages complex contracting actions for laboratory diagnostics, biotechnology research, and public health data systems, ensuring timely delivery of mission-critical capabilities to respond to infectious disease threats and strengthen national laboratory infrastructure. His work spans the full acquisition lifecycle—from market research and solicitation development to contract award and performance monitoring—with a focus on high-stakes, science-driven procurements that enable rapid response and surveillance operations. Lorimer maintains consistent working relationships with leading providers of analytical instrumentation, clinical diagnostics, and biotechnology services, including General Dynamics Information Technology, Cepheid, MRIGLOBAL, GlaxoSmithKline, and New York City Health & Hospitals Corp. These partnerships reflect a preference for established vendors with proven expertise in deploying validated diagnostic platforms, biosafety-compliant research tools, and large-scale epidemiological data systems. His contracting patterns emphasize technical rigor, regulatory compliance, and scalability to support nationwide public health initiatives. Lorimer’s procurement portfolio reflects a strong preference for full and open competition, with 100% of awards issued under no set-aside classifications. This approach underscores a strategic emphasis on accessing the broadest possible pool of technical expertise, particularly in specialized domains where only a limited number of vendors possess the necessary certifications, validation protocols, or manufacturing capabilities required for federal public health applications. His primary NAICS focus areas include analytical laboratory instrument manufacturing, testing laboratory services, and biotechnology research and development, indicating deep expertise in procuring advanced diagnostic equipment, clinical assay services, and novel pathogen detection technologies. He regularly engages with vendors providing PCR-based platforms, biospecimen handling systems, and integrated data analytics tools essential to modern disease surveillance and outbreak response.